Episode description
Get ready for a crash course in glycoengineering as Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, breaks down the significance of modifying glycans in biopharmaceuticals.
Explore the science behind glycoengineering and its potential to enhance the properties of therapeutic proteins.
Key Insights:
- Unlock new frontiers in glycoengineering
- Explore the potential of glycoengineering to revolutionize biopharmaceuticals
- Ensure seamless integration of glycoengineering into production processes
Don't miss this episode as Thomas unveils the trends that will shape the future of glycoengineering, offering actionable insights for scientists, entrepreneurs, and biotech enthusiasts alike.
Connect with Thomas Rexer:
LinkedIn: https://www.linkedin.com/in/thomas-rexer
Website: www.eversyn.de
Next Step:
Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com